$610 Million is the total value of TCG Crossover Management, LLC's 22 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 50.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
GERN | Buy | GERON CORP | $75,723,191 | +96.4% | 23,589,779 | +32.8% | 12.42% | +65.3% |
COGT | Buy | COGENT BIOSCIENCES INC | $66,671,537 | +70.2% | 5,631,042 | +55.1% | 10.93% | +43.2% |
AVTE | Buy | AEROVATE THERAPEUTICS INC | $37,751,849 | +73.1% | 2,201,274 | +103.6% | 6.19% | +45.6% |
New | ICOSAVAC, INC | $36,777,781 | – | 3,703,704 | +100.0% | 6.03% | – | |
New | AN2 Therapeutics, Inc. | $10,959,220 | – | 1,289,320 | +100.0% | 1.80% | – | |
CCCC | Buy | C4 THERAPEUTICS, INC. | $3,510,579 | -10.6% | 1,276,574 | +2.1% | 0.58% | -24.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
COGENT BIOSCIENCES INC | 8 | Q3 2023 | 15.6% |
AEROVATE THERAPEUTICS INC | 8 | Q3 2023 | 6.5% |
TYRA BIOSCIENCES INC | 8 | Q3 2023 | 6.2% |
ENTRADA THERAPEUTICS INC | 8 | Q3 2023 | 5.3% |
MERUS N.V. | 8 | Q3 2023 | 3.4% |
IVERIC BIO INC | 7 | Q2 2023 | 24.4% |
Geron Corporation | 7 | Q3 2023 | 12.4% |
ACLARIS THERAPEUTICS INC | 7 | Q2 2023 | 7.9% |
KURA ONCOLOGY INC | 7 | Q3 2023 | 9.1% |
ALPINE IMMUNE SCIENCES INC | 7 | Q2 2023 | 7.6% |
View TCG Crossover Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Silence Therapeutics plc | August 19, 2022 | 6,314,625 | 5.9% |
CymaBay Therapeutics, Inc. | November 29, 2021 | 5,905,400 | 7.0% |
Cogent Biosciences, Inc. | November 17, 2021 | 2,716,042 | 6.8% |
Tyra Biosciences, Inc. | September 29, 2021 | 937,500 | 2.2% |
Viridian Therapeutics, Inc.\DE | September 29, 2021 | 1,314,000 | 8.2% |
View TCG Crossover Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
SC 13G | 2022-08-19 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
View TCG Crossover Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.